1 Global Antimicrobial Peptides Market Size (Revenue) and CAGR (2024-2033)
Global Antimicrobial Peptides market generated revenue of USD 358.24 Million in 2024 with a CAGR of 14.96% during 2024 to 2033.
The Antimicrobial Peptides market is in a dynamic phase, with significant growth opportunities balanced by challenges that require strategic navigation. The market’s future looks promising, with the CAGR indicating a sustained period of expansion. Companies in this industry are advised to focus on research and development, product innovation, and service improvement to gain a competitive edge and capture a larger market share.
Figure Global Antimicrobial Peptides Market Size (M USD) Outlook (2024-2033)
2 Antimicrobial Peptides Industry Technology Status and Trends
Antimicrobial Peptides have attracted much attention due to their unique broad-spectrum antibacterial properties, modulation of innate immunity, and resistance to drug resistance. So far, more than 2,600 Antimicrobial Peptides have been discovered, and they are widely distributed in organisms such as viruses, bacteria, fungi, fish, birds, insects, amphibians, mollusks, and mammals.
At present, there are three main production methods of Antimicrobial Peptides: natural extraction, chemical synthesis and bioengineering fermentation. Natural Antimicrobial Peptides mainly come from animals and plants, with extremely low content, and the extraction process is very complicated; chemical synthesis methods are expensive, not suitable for industrial production, and cannot be widely used; bioengineering fermentation is the use of fermentation technology to achieve industry, with stable quality and low cost Advantages, is the industry-recognized best way to large-scale production. Therefore, molecular design, optimization of expression system, structural modification and modification of Antimicrobial Peptides based on their physical and chemical properties are the primary issues in the research and development stage, and are also the main factors controlling the overall large-scale production.
At this stage, the molecular modification of Antimicrobial Peptides mainly pursues the two goals of reducing toxicity and improving its antibacterial activity. The transformation methods mainly include residue substitution and truncation, construction of hybrid peptides, etc. Many artificially engineered molecular designs are based on their various amino acid composition ratios and sequences. There are two types of transformation methods, one is to change the sequence of amino acids without changing their types; the other is to increase or decrease the types of amino acids, so that they can produce new properties due to structural changes. Mutation can cause substitution, insertion, frameshift or deletion of amino acid residues, etc., and is a common method for studying the structure and function of antimicrobial peptides. Molecular modification of Antimicrobial Peptides can produce significant changes in its functions, such as improved antibacterial activity, enhanced anticancer ability, high expression, and reduced hemolysis. Some structures in natural Antimicrobial Peptides have no effect on their activity, and even larger peptide chains can affect the stability and immunogenicity of antimicrobial peptides. Therefore, truncation to remove its redundant structure and maintain the active part is one of the important improvement measures.
The expression systems of Antimicrobial Peptides are divided into three categories: baculovirus expression system, eukaryotic expression system and prokaryotic expression system. These three expression systems have their own outstanding characteristics, so different Antimicrobial Peptides can choose the corresponding expression system according to their own properties and characteristics during expression, and systematically optimize them by modifying them. The prokaryotic expression system is generally an E. coli expression system, which has the characteristics of simple culture conditions and fast reproduction speed, and is easy to carry out large-scale production. However, because it is a prokaryotic organism, it does not have the precise protein processing system of eukaryotes, and the expression amount is very small. Yeast expression host is one of the most commonly used eukaryotic expression systems that can express and precisely modify proteins. Compared with prokaryotic expression systems, yeast expression systems are mainly characterized by the modification and processing of proteins after expression, such as glycosylation. retouch. The baculovirus expression system has a wide range of applications and high expression efficiency. Compared with the previous two expression systems, the baculovirus expression system is relatively simple to operate, simple to culture insect cells, and has low economic costs. Post-protein modification processing function. Due to the biological characteristics of microorganisms such as easy cultivation and fast growth and reproduction, the production of Antimicrobial Peptides by microbial fermentation has the advantages of short fermentation cycle, low production cost, simple operation and easy industrial production. Therefore, the use of microbial fermentation to produce Antimicrobial Peptides has more application potential.
3 Global Antimicrobial Peptides Market by Type in 2024
The Antimicrobial Peptides (AMPs) market has been garnering significant attention due to their potential as effective alternatives to conventional antibiotics. In 2024, the global AMP market demonstrated substantial growth, with various product types contributing to this expansion.
Recombinant AMPs: Recombinant AMPs captured a substantial market share in 2024, reflecting the industry’s preference for their consistency and scalability. With a market value of 163.34 million U.S. dollars, Recombinant AMPs accounted for approximately 45.59% of the total AMP market. This product type’s dominance can be attributed to the precision and control offered by recombinant DNA technology, which is particularly valuable in pharmaceutical applications where purity and potency are paramount.
Natural AMPs: Natural AMPs also performed strongly, with a market value of 194.90 million U.S. dollars, representing about 54.41% of the total market. The appeal of Natural AMPs lies in their eco-friendliness and the growing consumer preference for natural products. They are particularly popular in agriculture and food additive applications, where there is a growing trend towards organic and sustainable solutions.
In 2024, the Antimicrobial Peptides market showcased a competitive landscape with Natural AMPs holding the largest market share and demonstrating the fastest growth rate. This trend underscores the market’s responsiveness to consumer preferences and environmental concerns. Recombinant AMPs, while capturing a slightly smaller market share, continue to be a significant player, particularly in the pharmaceutical sector. As the market evolves, it is expected that both product types will continue to grow, driven by innovations in technology, increasing demand for sustainable solutions, and the ongoing battle against antimicrobial resistance. The Antimicrobial Peptides market is set to be a key player in the global effort to combat infections and maintain public health.
Table Global Antimicrobial Peptides Market Size and Share by Type in 2024
|
Type |
Market Size (M USD) |
Market Share (%) |
|---|---|---|
|
Recombinant |
163.34 |
45.59% |
|
Natural |
194.90 |
54.41% |
4 Global Antimicrobial Peptides Market by Application in 2024
Antimicrobial Peptides (AMPs) have emerged as a critical component in various industries due to their unique properties in combating microbial infections. In 2024, the AMP market witnessed significant growth across different applications, each playing a pivotal role in their respective sectors.
Pharmaceutical: The pharmaceutical application held the largest market share in 2024, with a value of 140.98 million U.S. dollars, accounting for approximately 39.35% of the total market. This dominance can be attributed to the continuous need for new antimicrobial agents in human medicine and the growing focus on research and development in this area.
Animal Feed: Animal feed was another significant application, with a market value of 89.86 million U.S. dollars, representing about 25.08% of the market. The increasing demand for natural animal feed additives and the push for antibiotic-free livestock farming have propelled this application’s growth.
Food Additive: The food additive segment had a market value of 63.92 million U.S. dollars, capturing around 17.84% of the market. The rising consumer awareness about food safety and the preference for natural preservatives have contributed to the growth of this segment.
Agriculture: Agricultural applications had a market value of 47.55 million U.S. dollars, constituting about 13.27% of the total market. The push for sustainable farming practices and the need for eco-friendly pesticides have supported the growth of AMPs in agriculture.
In 2024, the Antimicrobial Peptides market demonstrated a diverse application landscape with the pharmaceutical sector claiming the largest market share and the fastest growth rate. This trend underscores the critical role of AMPs in addressing the global challenge of antibiotic resistance and the growing demand for natural solutions in various industries. As the market continues to evolve, driven by technological advancements and consumer preferences, AMPs are poised to play an increasingly significant role in ensuring public health and food safety. The Antimicrobial Peptides market is set to be a key player in the global effort to combat infections and maintain sustainable agricultural practices.
Table Global Antimicrobial Peptides Market Size and Share by Application in 2024
|
Application |
Market Size (M USD) |
Market Share (%) |
|---|---|---|
|
Pharmaceutical |
140.98 |
39.35% |
|
Animal Feed |
89.86 |
25.08% |
|
Food Additive |
63.92 |
17.84% |
|
Agriculture |
47.55 |
13.27% |
|
Others |
15.93 |
4.45% |
5 Global Antimicrobial Peptides Market by Region in 2024
The Antimicrobial Peptides (AMPs) market has been at the forefront of the battle against antimicrobial resistance, with regions across the globe recognizing their importance in various sectors. In 2024, the market saw significant developments, with different regions contributing distinctively to the overall growth.
United States: United States, with its strong focus on technological advancements and healthcare, led the AMP market in 2024. The region’s market value reached 139.92 million U.S. dollars. This dominance can be attributed to the region’s robust healthcare infrastructure, significant research and development investments, and the presence of major pharmaceutical companies.
Europe: Europe followed closely with a market value of 83.99 million U.S. dollars. The region’s strong regulatory support for innovative medicines and a well-established pharmaceutical industry contributed to its substantial share.
China: China demonstrated considerable growth, with a market value of 56.36 million U.S. dollars. The region’s rapid economic development, increasing healthcare expenditure, and growing demand for novel antimicrobial solutions were key factors driving this growth.
The global Antimicrobial Peptides market is characterized by diverse regional dynamics, with each region playing a distinct role in shaping the market’s trajectory. In 2024, United States stands out as the largest market by revenue, benefiting from its manufacturing prowess and economic might. Meanwhile, India exhibits the most promising growth prospects, offering opportunities for investors and manufacturers alike. As the market evolves, it is essential for stakeholders to understand these regional trends to navigate the competitive landscape effectively and capitalize on emerging opportunities.
Table Global Antimicrobial Peptides Market Size, Region Wise in 2024
|
Region |
Market Size (M USD) |
|---|---|
|
United States | |
|
Europe |
83.99 |
|
China |
56.36 |
|
Japan |
19.36 |
|
India |
7.33 |
|
Southeast Asia |
9.25 |
|
Latin America |
10.50 |
|
Middle East and Africa |
7.47 |
6 Global Antimicrobial Peptides Market Top 3 Players
Company Introduction and Business Overview: Royal DSM N.V, established in 1902 and headquartered in the Netherlands, is a global science-based company active in Nutrition, Health, and Bioscience. DSM’s mission is to create business solutions that nourish, protect, and improve performance while contributing to a circular and sustainable economy. With a sales region spanning worldwide, DSM has established itself as a key player in the AMP market.
Products Offered: DSM offers a range of AMP products, with Delvo®Nis being a standout. Delvo®Nis is a fermentation-based peptide effective against bacterial spoilage, used in various heat-processed foods like cheese, dairy desserts, meat, beverages, and baking products. Based on nisin, it extends shelf life with no effect on taste and even improves product quality by helping lower processing temperatures.
Revenue in 2022: In 2022, Royal DSM N.V reported a revenue of 15.34 million U.S. dollars from its Antimicrobial Peptides segment, marking a significant position in the market. With a gross margin of 50.31%, DSM continues to be a profitable and influential company in the AMP industry.
Company Introduction and Business Overview: Xellia, founded in 1958 and based in Denmark, is a global leader in the manufacturing of specialty anti-infective treatments. Xellia’s products are used worldwide, and the company is committed to delivering innovative solutions to combat infections and improve patient outcomes.
Products Offered: Xellia’s product portfolio includes Bacitracin, a group of polypeptides with antibiotic activity against a variety of Gram-positive bacteria. It is used for local treatment of skin, ear, and eye infections, and in some parts of the world, for intramuscular use in infants for pneumonia and empyema caused by susceptible staphylococci.
Revenue in 2022: In 2022, Xellia reported a revenue of 14.37 million U.S. dollars from its Antimicrobial Peptides segment, with a gross margin of 50.42%. This revenue places Xellia as a strong competitor in the AMP market, reflecting its commitment to innovation and quality.
Shenzhen Sunsmile Biotechnology Co.,Ltd
Company Introduction and Business Overview: Established in 2005 and headquartered in China, Shenzhen Sunsmile Biotechnology Co.,Ltd is a company that primarily operates in Asia and Europe. Sunsmile is known for its genetic engineering technology and fermentation technology, producing high-content and high-titer compound antimicrobial peptide products.
Products Offered: Sunsmile’s flagship product, Too Easy W Enhanced, is part of their veterinary drug raw materials series. This product is developed through patented genetic engineering technology, introducing various antimicrobial peptide genes into genetically engineered bacteria for large-scale recombinant expression.
Revenue in 2022: In 2022, Shenzhen Sunsmile Biotechnology Co.,Ltd reported a revenue of 12.89 million U.S. dollars from its Antimicrobial Peptides segment, achieving a gross margin of 50.55%. This performance highlights Sunsmile’s growing presence in the AMP market and its focus on delivering effective and innovative products.
Table Global Antimicrobial Peptides Revenue Share of Top3 Players in 2022
|
Company |
2022 |
|
Royal DSM N.V |
5.74% |
|
Xellia |
5.38% |
|
Shenzhen Sunsmile Biotechnology Co.,Ltd |
4.82% |